<DOC>
	<DOCNO>NCT02779751</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy abemaciclib combination pembrolizumab participant advance non-small cell lung cancer ( NSCLC ) hormone receptor positive ( HR+ ) , human epidermal growth factor receptor negative ( HER2- ) breast cancer .</brief_summary>
	<brief_title>A Study Abemaciclib ( LY2835219 ) Participants With Non-Small Cell Lung Cancer Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Have Stage IV diagnosis 1 following : Part A : NSCLC ( Kirsten rat sarcoma mutant [ KRAS mt ] , PDL1+ ) ; Part B : NSCLC ( squamous histology ) ; Part C : metastatic breast cancer ( HR+ , HER2 ) . Part A : must chemotherapy naïve metastatic NSCLC Part B : must receive least 1 prior therapy contain platinumbased chemotherapy advanced/metastatic NSCLC Part C : must previously receive prior treatment least 1 2 chemotherapy regimen metastatic setting Are amenable provide tumor tissue prior treatment provide tumor tissue treatment initiation ( mandatory ) . Have presence measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) . Have performance status ( PS ) ≤1 Eastern Cooperative Oncology Group ( ECOG ) scale . Have discontinue previous treatment cancer recover acute effect therapy . Have estimate life expectancy ≥12 week . Have personal history follow condition : syncope either unexplained cardiovascular etiology , ventricular arrhythmia ( include limit ventricular tachycardia ventricular fibrillation ) , sudden cardiac arrest . Exception : subject control atrial fibrillation &gt; 30 day prior study treatment eligible . Have central nervous system ( CNS ) metastasis development associate neurological change 14 day prior receive study drug . Have correct QT interval &gt; 470 millisecond screen electrocardiogram ( ECG ) . Have history interstitial lung disease pneumonitis . Have history active autoimmune disease , syndrome require systemic steroid autoimmune agent past 2 year . Have receive live vaccination within 30 day study start . Have receive prior treatment anti PD1 , antiprogrammed death ligand 1 ( PDL1 ) , anti cytotoxic Tlymphocyteassociated protein 4 ( CTLA4 ) agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>